Lidocaine vaginal - Enhance Pharmaceuticals
Latest Information Update: 20 Jan 2022
At a glance
- Originator Enhance Pharmaceuticals
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Cell membrane permeability inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaesthesia
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Anaesthesia in USA (Vaginal)
- 17 Jun 2002 Enhance Pharmaceuticals has been acquired by Barr Laboratories
- 28 Mar 2002 Barr Laboratories expects to acquire Enhance, subject to conditions, by June 30, 2002